Antiagregação e anticoagulação na intervenção coronária
25225
Bibliografia
1. Gabriel S, Stefan J, Atar D, et al. ESC Guidelines for the management of acute myocardial
infarction in patients presenting with ST‑segment elevation. Eur Heart J. 2012;33:2569‑619.
2. ISIS‑2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin,
both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS‑2. Lancet.
1988;13:349‑60.
3. Zijlstra F, Ernst N, de Boer MJ, et al. Influence of prehospital administration of aspirin and
heparina on initial patency of infarct‑related artery in patients with acute ST elevation myocardial
infarction. J Am Coll Cardiol. 2002;39:1733‑7.
4. Montalescot G, Hof AW, Lapostolle F, et al. Prehospital ticagrelor in ST‑segment elevation
myocardial infarction. N Engl J Med. 2014;371:1016‑27.
5. Sebastine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic
therapy for myocardial infarction with ST‑segment elevation. N Engl J Med. 2005;352:1179‑89.
6. Vlarr PJ, Svilaas T, Damman K, et al. Impact of pretreatment with clopidogrel on initial patency
and outcome in patients treated with primary percutaneous coronary intervention for
ST‑segment elevation myocardial infarction: a systematic review. Circulation. 2008;118:1828.
7. Montalescot G,Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients
undergoing percutaneous coronary intervention for ST‑elevation myocardial infarction
(TRITONTIMI 38): double‑blind, randomized controlled trial. Lancet. 2009;373:723‑31.
8. Steg PG, James S, Harrington RA, et al.Ticagrelor versus clopidogrel in patients with ST‑elevation
acute coronary syndromes intended for reperfusion with primary percutaneous coronary
intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Circulation. 2010;122:2131‑41.
9. SerebruanyVL.TheTRITON versus PLATO trials: differences beyond platelet inhibition.Thromb
Haemost. 2010;103:259‑61.
10. De Luca G, Suryapranata H, Stone GW, et al.Abciximab as adjunctive therapy to reperfusion in
acute ST‑segment elevation myocardial infarction: a meta‑analysis of randomized trials. JAMA.
2005;293:1759.
11. Stephan W, Philippe K, Fernando A, et al. 2014 ESC/EACTS Guidelines on myocardial
revascularization. Eur Heart J. 2014;35:2541‑2619
12. Shahzad A, Kemp I, Mars C, et al. Unfractionated heparin versus bivalirudin in primary
percutaneous coronary intervention (HEAT‑PPCI): an open‑label, single centre, randomised
controlled trial. Lancet. 2014;384:1849.
13. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in
patients with ST‑segment elevation myocardial infarction: the OASIS‑6 randomized trial. JAMA.
2006;295:1519‑30.
14. Mehran R, Lansky AJ, Witzenbichler B, et al. Bivalirudin in patients undergoing primary
angioplasty for acute myocardial infarction (HORIZONS‑AMI): 1‑year results of a randomized
controlled trial. Lancet. 2009;374:1149‑59.
15. Steg PG, van ’t Hof A, Hamm CW, et al EUROMAX Investigators. Bivalirudin Started during
Emergency Transport for Primary PCI. N Engl J Med. 2013;369:2207–2217.
